PCO
MCID: PLY011
MIFTS: 64

Polycystic Ovary Syndrome (PCO)

Categories: Blood diseases, Endocrine diseases, Metabolic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Polycystic Ovary Syndrome

MalaCards integrated aliases for Polycystic Ovary Syndrome:

Name: Polycystic Ovary Syndrome 38 12 25 37 55 43 44 15 73
Polycystic Ovarian Syndrome 76 53 25 15
Polycystic Ovaries 12 29 55
Pcos 12 53 25
Polycystic Ovarian Disease 12 25
Stein-Leventhal Syndrome 12 25
Sclerocystic Ovaries 25 73
Multicystic Ovaries 12 25
Polycystic Ovary Syndrome, Susceptibility to 6
Sclerocystic Ovarian Degeneration 25
Sclerocystic Ovary Syndrome 25
Cystic Disease of Ovaries 25
Cystic Disease of Ovary 25
Stein-Leventhal Synd. 12
Polycystic Ovary 12
Pcod 25
Pco 25

Classifications:



External Ids:

Disease Ontology 12 DOID:11612
ICD10 33 E28.2
ICD9CM 35 256.4
MeSH 44 D011085
NCIt 50 C26862
SNOMED-CT 68 69878008
KEGG 37 H01739

Summaries for Polycystic Ovary Syndrome

MedlinePlus : 43 Polycystic ovary syndrome (PCOS) happens when a woman's ovaries or adrenal glands produce more male hormones than normal. PCOS causes cysts (fluid-filled sacs) to grow on the ovaries. Symptoms include Irregular menstrual periods Infertility Pelvic pain Excess hair growth on the face, chest, stomach, or thighs Weight gain Acne or oily skin Patches of thickened skin Women with PCOS are at higher risk of diabetes, metabolic syndrome, heart disease, and high blood pressure. PCOS is more common in women who have obesity, or have a mother or sister with PCOS. To diagnose PCOS, your health care provider may do a physical exam, pelvic exam, blood tests, and an ultrasound. There is no cure, but diet, exercise, and medicines can help control the symptoms. Birth control pills help women have normal periods, reduce male hormone levels, and clear acne. Treatments for infertility caused by PCOS may include medicines, surgery, and in vitro fertilization (IVF). NIH: National Institute of Child Health and Human Development

MalaCards based summary : Polycystic Ovary Syndrome, also known as polycystic ovarian syndrome, is related to aromatase deficiency and cortisone reductase deficiency, and has symptoms including pelvic pain An important gene associated with Polycystic Ovary Syndrome is ENSG00000234940 (), and among its related pathways/superpathways are Glucose / Energy Metabolism and HIF-1 signaling pathway. The drugs Metformin and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include ovary, heart and skin, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Disease Ontology : 12 A syndrome characterized by hyperandrogenism, polycystic ovaries, hirsutism, oligomenorrhea or amenorrhea, anovulation and excessive body weight.

Genetics Home Reference : 25 Polycystic ovary syndrome is a condition that affects women in their child-bearing years and alters the levels of multiple hormones, resulting in problems affecting many body systems.

NIH Rare Diseases : 53 Polycystic ovarian syndrome (PCOS) is a health problem that can affect a woman's menstrual cycle, ability to have children, hormones, heart, blood vessels, and appearance. Women with this condition typically have high levels of  hormones called androgens, missed or irregular periods, and many small cysts in their ovaries. The cause of PCOS is unknown, but probably involves a combination of genetic and environmental factors. Treatment for PCOS may involve birth control pills and medications for diabetes and infertility. Medicines called anti-androgens are also used to speed the growth of hair and clear acne.

Wikipedia : 76 Polycystic ovary syndrome (PCOS) is a set of symptoms due to elevated androgens (male hormones) in... more...

Related Diseases for Polycystic Ovary Syndrome

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 267)
# Related Disease Score Top Affiliating Genes
1 aromatase deficiency 32.6 CYP19A1 GNRH1 INS
2 cortisone reductase deficiency 32.4 CYP11A1 CYP17A1 CYP21A2
3 ovarian disease 32.1 CYP11A1 CYP19A1 GDF9 GNRH1 IGF1 INS
4 cytochrome p450 oxidoreductase deficiency 32.0 CYP17A1 CYP21A2
5 glucose intolerance 31.2 IGF1 INS INSR SHBG
6 infertility 31.2 CYP19A1 GDF9 GNRH1 PRL
7 hyperinsulinism 31.2 IGF1 INS INSR SHBG
8 diabetes mellitus 31.2 CAPN10 IGF1 INS INSR SHBG
9 gestational diabetes 31.1 CAPN10 INS INSR SHBG
10 hyperandrogenism 31.0 CYP17A1 CYP19A1 CYP21A2 GNRH1 IGF1 INS
11 anovulation 31.0 CYP19A1 GNRH1 IGF1 INS PRL SHBG
12 amenorrhea 30.9 GNRH1 PRL SHBG
13 insulin-like growth factor i 30.8 IGF1 INS INSR PRL SHBG
14 hyperprolactinemia 30.8 GNRH1 IGF1 PRL SHBG
15 acanthosis nigricans 30.8 IGF1 INS INSR PRL SHBG
16 precocious puberty 30.5 CYP19A1 CYP21A2 GNRH1
17 premature ovarian failure 1 30.5 CYP11A1 CYP19A1 GDF9 GNRH1 PRL SHBG
18 androgenic alopecia 30.4 CYP19A1 PRL SHBG
19 diabetes mellitus, noninsulin-dependent 30.4 CAPN10 GAS5 IGF1 INS INSR SHBG
20 central precocious puberty 30.3 GNRH1 IGF1
21 acromegaly 30.3 IGF1 INS PRL
22 lipoid congenital adrenal hyperplasia 30.3 CYP11A1 CYP17A1 CYP19A1 CYP21A2
23 breast disease 30.3 CYP19A1 IGF1 PRL SHBG
24 hyperglycemia 30.2 IGF1 INS INSR
25 galactorrhea 30.2 IGF1 PRL
26 endometrial cancer 30.2 CYP19A1 GAS5 GNRH1 IGF1 INS SHBG
27 estrogen excess 30.2 CYP19A1 PRL SHBG
28 conn's syndrome 30.2 CYP11A1 CYP17A1 CYP21A2 PRL
29 empty sella syndrome 30.2 GNRH1 IGF1 PRL
30 hypogonadotropism 30.1 GNRH1 PRL
31 adrenal adenoma 30.1 CYP11A1 CYP17A1 CYP21A2
32 hypothalamic disease 30.1 GNRH1 PRL
33 pituitary gland disease 30.1 GNRH1 IGF1 INS PRL
34 alopecia, androgenetic, 1 30.0 CYP19A1 CYP21A2 SHBG
35 body mass index quantitative trait locus 11 30.0 CAPN10 CYP21A2 IGF1 INS INSR SHBG
36 transsexualism 30.0 CYP17A1 CYP19A1 CYP21A2
37 luteoma 30.0 CYP19A1 CYP21A2
38 breast cancer 28.9 CYP17A1 CYP19A1 GAS5 GNRH1 IGF1 INS
39 polycystic ovary syndrome 1 12.7
40 proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome 11.9
41 hair-an syndrome 11.3
42 acth-independent macronodular adrenal hyperplasia 11.2
43 ovarian cyst 11.2
44 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 11.2
45 hypoparathyroidism, sensorineural deafness, and renal disease 11.1
46 retinitis pigmentosa-intellectual disability-deafness-hypogonadism syndrome 11.1
47 body mass index quantitative trait locus 1 10.7
48 depression 10.5
49 fatty liver disease 10.5
50 liver disease 10.5

Graphical network of the top 20 diseases related to Polycystic Ovary Syndrome:



Diseases related to Polycystic Ovary Syndrome

Symptoms & Phenotypes for Polycystic Ovary Syndrome

UMLS symptoms related to Polycystic Ovary Syndrome:


pelvic pain

MGI Mouse Phenotypes related to Polycystic Ovary Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 CAPN10 CYP11A1 CYP17A1 CYP19A1 FST GDF9
2 endocrine/exocrine gland MP:0005379 10.02 CAPN10 CYP11A1 CYP19A1 FST GDF9 GNRH1
3 adipose tissue MP:0005375 9.85 CAPN10 CYP17A1 CYP19A1 IGF1 INS INSR
4 liver/biliary system MP:0005370 9.7 CAPN10 CYP11A1 CYP19A1 GNRH1 INS INSR
5 renal/urinary system MP:0005367 9.5 CAPN10 CYP17A1 CYP19A1 GNRH1 IGF1 INS
6 reproductive system MP:0005389 9.32 CYP11A1 CYP17A1 CYP19A1 FST GDF9 GNRH1

Drugs & Therapeutics for Polycystic Ovary Syndrome

Drugs for Polycystic Ovary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 363)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
2
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
3
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 427-51-0
4
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
5 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
6
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-63-6 5991
7
Orlistat Approved, Investigational Phase 4,Phase 2,Not Applicable 96829-58-2 3034010
8
Simvastatin Approved Phase 4,Phase 3,Not Applicable 79902-63-9 54454
9
Resveratrol Approved, Experimental, Investigational Phase 4,Phase 1,Not Applicable 501-36-0 445154
10
Ganirelix Approved Phase 4,Early Phase 1 123246-29-7, 124904-93-4 25081094
11
Drospirenone Approved Phase 4,Phase 3,Phase 1,Not Applicable 67392-87-4 68873
12
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
13
Hydrocortisone acetate Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-03-3
14
Pioglitazone Approved, Investigational Phase 4,Not Applicable,Early Phase 1 111025-46-8 4829
15
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-23-7 5754
16
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
17
Menotropins Approved Phase 4,Phase 2,Phase 1,Not Applicable 61489-71-2, 9002-68-0 5360545
18
Zinc Approved, Investigational Phase 4,Early Phase 1,Not Applicable 7440-66-6
19
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
20
Acarbose Approved, Investigational Phase 4,Not Applicable 56180-94-0 441184
21
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
22
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 71-58-9
23
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
24
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 616-91-1 12035
25
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
26
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
27
Epinephrine Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 51-43-4 5816
28
Racepinephrine Approved Phase 4,Not Applicable,Early Phase 1 329-65-7 838
29
Citalopram Approved Phase 4 59729-33-8 2771
30
Rosiglitazone Approved, Investigational Phase 4,Not Applicable 122320-73-4 77999
31
Leuprolide Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 53714-56-0 657181 3911
32
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
33
Methylcobalamin Approved, Experimental, Investigational Phase 4,Not Applicable 13422-55-4
34
Hydroxocobalamin Approved Phase 4,Not Applicable 13422-51-0 11953898 44475014
35
Alogliptin Approved Phase 4 850649-61-5 11450633
36
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
37
Tamoxifen Approved Phase 4 10540-29-1 2733526
38
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
39
Desogestrel Approved Phase 4,Phase 3 54024-22-5 40973
40
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
41
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
42
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
43
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
44
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 77-92-9 311
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
46
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-14-6 5280793
47
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 67-97-0 5280795 6221
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1406-16-2
49
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 73-31-4 896
50
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938

Interventional clinical trials:

(show top 50) (show all 604)
# Name Status NCT ID Phase Drugs
1 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
2 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
3 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
4 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
5 Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT02766803 Phase 4 Simvastatin and micronized trans-resveratrol
6 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
7 Metformin in Infertile PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
8 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
9 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
10 PCOS, Therapy and Markers of Cardiovascular Risk Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
11 Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
12 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
13 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
14 Adding L-carnitine in Clomiphene Resistant Polycystic Ovary Improves the Quality of Ovulation and the Pregnancy Outcome Unknown status NCT01665547 Phase 4 l-carnitine
15 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
16 Corifollitropin Alfa Application in PCOS Patients Unknown status NCT02215135 Phase 4 Corifollitropin alfa
17 Metformin for the Treatment of Unexplained Oligozspermia Unknown status NCT01529177 Phase 4 Metformin / clomid / hCG;Clomiphene citrate / hCG
18 Polycystic Ovary Syndrome - Improving Outcomes Completed NCT01504321 Phase 4 Moxonidine;Placebo
19 Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome Completed NCT03630341 Phase 4 Clomiphene Citrate 50mg;L-carnitine;Placebo Oral Tablet
20 Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome Completed NCT00679679 Phase 4 Metformin;Placebo
21 N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Completed NCT02239107 Phase 4 N-Acetyl cysteine
22 Trial With Metformin in Women With Polycystic Ovary Syndrome Completed NCT02280057 Phase 4 Metformin;Placebo
23 PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene Completed NCT00795808 Phase 4 Metformin;Placebo;Metformin + Clomiphene;Metformin;Clomiphene
24 The Effects of Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat in the Polycystic Ovary Syndrome Completed NCT00620529 Phase 4
25 Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome Completed NCT01118598 Phase 4 tredaptive (nicotinic acid/ laropiprant);placebo
26 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
27 LIPT - Liraglutide in Polycystic Ovary Syndrome Completed NCT02073929 Phase 4 Liraglutide;placebo
28 The Effects of Vitamin D on Angiogenic Factors in Women With Polycystic Ovary Syndrome Completed NCT02460380 Phase 4 Vitamin D3
29 The Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination Completed NCT01219101 Phase 4 clomiphene citrate with ethinyl esteradiol;clomiphene citrate with plasebo
30 Metformin and Folate Supplementation in Polycystic Ovary Syndrome (PCOS) Patients Completed NCT00953355 Phase 4 Folate plus metformin;Placebo plus metformin
31 Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS) Completed NCT01004068 Phase 4 Clomiphene citrate
32 Pioglitazone Treatment in Polycystic Ovary Syndrome Completed NCT00145340 Phase 4 pioglitazone
33 Polycystic Ovary Syndrome and Liraglutide Completed NCT01899430 Phase 4 liraglutide;metformin
34 Metformin and Folate in Pregnant Polycystic Ovary Syndrome(PCOS) Women Completed NCT01115140 Phase 4 metformin plus placebo;Metformin plus folic acid;placebo plus folic acid;placebo alone
35 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
36 The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS Completed NCT01961180 Phase 4 Cipralex;Placebo
37 Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin Completed NCT01911468 Phase 4 metformin;liraglutide;metformin and liraglutide
38 PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome Completed NCT02037672 Phase 4 metformin;metformin and roflumilast
39 PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome Completed NCT02187250 Phase 4 metformin;liraglutide;roflumilast
40 Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study Completed NCT00640224 Phase 4 rosiglitazone;drospirenone/ethinyl estradiol
41 Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
42 Incretin Effect in PCOS Women Completed NCT01892254 Phase 4 Metformin;Placebo
43 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) Completed NCT00805935 Phase 4 Menotropin;Progesterone vaginal insert;Follitropin beta;Progesterone in oil;leuprolide acetate
44 Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles Completed NCT01233206 Phase 4 Metformin;Placebo administration
45 Metformin Suspension and Insulin Sensitivity Completed NCT00437333 Phase 4 Metformin cloridrate
46 The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS Completed NCT02866786 Phase 4 Metformin;ethinyl estradiol and cyproterone acetate
47 Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome Completed NCT01675843 Phase 4
48 Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome Completed NCT01540747 Phase 4
49 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
50 Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome Completed NCT03122041 Phase 4 Sitagliptin

Search NIH Clinical Center for Polycystic Ovary Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: polycystic ovary syndrome

Genetic Tests for Polycystic Ovary Syndrome

Genetic tests related to Polycystic Ovary Syndrome:

# Genetic test Affiliating Genes
1 Polycystic Ovaries 29

Anatomical Context for Polycystic Ovary Syndrome

MalaCards organs/tissues related to Polycystic Ovary Syndrome:

41
Ovary, Heart, Skin, Liver, Endothelial, Pituitary, Testes

Publications for Polycystic Ovary Syndrome

Articles related to Polycystic Ovary Syndrome:

(show top 50) (show all 4536)
# Title Authors Year
1
Similarities and differences in the reproductive phenotypes of women with congenital hypogonadotrophic hypogonadism caused by GNRHR mutations and women with polycystic ovary syndrome. ( 30476149 )
2019
2
Bidirectional Mendelian randomization to explore the causal relationships between body mass index and polycystic ovary syndrome. ( 30496407 )
2019
3
Downregulation of Extracellular Matrix and Cell Adhesion Molecules in Cumulus Cells of Infertile Polycystic Ovary Syndrome Women with and without Insulin Resistance. ( 30507086 )
2019
4
Urinary concentration of personal care products and polycystic ovary syndrome: A case-control study. ( 30265948 )
2019
5
Association between The Number of Retrieved Mature Oocytes and Insulin Resistance or Sensitivity in Infertile Women with Polycystic Ovary Syndrome. ( 30291692 )
2019
6
miR-323-3p regulates the steroidogenesis and cell apoptosis in polycystic ovary syndrome (PCOS) by targeting IGF-1. ( 30300681 )
2019
7
Association between arginase-containing platelet-derived microparticles and altered plasma arginine metabolism in polycystic ovary syndrome. ( 30367832 )
2019
8
Follicular dynamics of glycerophospholipid and sphingolipid metabolisms in polycystic ovary syndrome patients. ( 30121347 )
2019
9
Long-term testosterone treatment during pregnancy does not alter insulin or glucose profile in a sheep model of polycystic ovary syndrome. ( 28851248 )
2019
10
Correction to: Seyyed Abootorabi et al., The effect of vitamin D supplementation on insulin resistance, visceral fat and adiponectin in vitamin D deficient women with polycystic ovary syndrome: a randomized placebo-controlled trial. ( 29447022 )
2018
11
Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome. ( 29941488 )
2018
12
Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance. ( 29068242 )
2018
13
Hyperandrogenism Enhances Muscle Strength After Progressive Resistance Training, Independent of Body Composition, in Women With Polycystic Ovary Syndrome. ( 29927897 )
2018
14
Infertile polycystic ovary syndrome patients undergoing in vitro fertilization with the gonadotropin-releasing hormone-antagonist protocol: role of hyperandrogenism. ( 29376451 )
2018
15
Authors' reply re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. ( 29226510 )
2018
16
Bariatric Surgery Improves Hyperandrogenism, Menstrual Irregularities, and Metabolic Dysfunction Among Women with Polycystic Ovary Syndrome (PCOS). ( 29500679 )
2018
17
Limitations of insulin resistance assessment in polycystic ovary syndrome. ( 29436386 )
2018
18
Gut Microbial Diversity in Women with Polycystic Ovary Syndrome Correlates with Hyperandrogenism. ( 29370410 )
2018
19
Wilms' Tumor 1 Overexpression in Granulosa Cells Is Associated with Polycystic Ovaries in Polycystic Ovary Syndrome Patients. ( 29414825 )
2018
20
Differential rate in decline in ovarian reserve markers in women with polycystic ovary syndrome compared with control subjects: results of a longitudinal study. ( 29428308 )
2018
21
Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome. ( 29109005 )
2018
22
Abnormality of Klotho Signaling Is Involved in Polycystic Ovary Syndrome. ( 28673204 )
2018
23
Association between Th1/Th2 immune imbalance and obesity in women with or without polycystic ovary syndrome. ( 29447491 )
2018
24
Functional Characterization of MicroRNA-27a-3p Expression in Human Polycystic Ovary Syndrome. ( 29029022 )
2018
25
Differential association of DENND1A genetic variants with polycystic ovary syndrome in Tunisian but not Bahraini Arab women. ( 29325736 )
2018
26
C-type natriuretic peptide: a link between hyperandrogenism and anovulation in a mouse model of polycystic ovary syndrome. ( 29739821 )
2018
27
Hidradenitis suppurativa is associated with polycystic ovary syndrome: a population-based analysis in the United States. ( 29378201 )
2018
28
Serum Levels of Angiopoietin-Like Protein 2 and Obestatin in Iranian Women with Polycystic Ovary Syndrome and Normal Body Mass Index. ( 29932432 )
2018
29
Aerobic Training Improves Quality of Life in Women with Polycystic Ovary Syndrome. ( 29443823 )
2018
30
The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review. ( 29309199 )
2018
31
Enlarged adipocytes in subcutaneous adipose tissue associated to hyperandrogenism and visceral adipose tissue volume in women with polycystic ovary syndrome. ( 29273198 )
2018
32
Polycystic Ovary Syndrome in Bipolar Affective Disorder: A Hospital-based Study. ( 29962567 )
2018
33
Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome. ( 29435121 )
2018
34
Fertility management experiences of women with polycystic ovary syndrome in Australia. ( 29939804 )
2018
35
Association of Decreased C1q/Tumor Necrosis Factor-Related Protein-5 Levels with Metabolic and Hormonal Disturbance in Polycystic Ovary Syndrome. ( 29964236 )
2018
36
Association between Major Dietary Patterns and Polycystic Ovary Syndrome: evidence from a case-control study. ( 29969571 )
2018
37
Re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. ( 29210151 )
2018
38
Non-targeted profiling of circulating microRNAs in women with polycystic ovary syndrome (PCOS): effects of obesity and sex hormones. ( 29410349 )
2018
39
Ovary stereological features and serum biochemical factors following induction of polycystic ovary syndrome with testosterone enanthate in mice: An experimental study. ( 29942935 )
2018
40
Polycystic ovary syndrome in mitochondrial disorders due mtDNA or nDNA variants. ( 29422990 )
2018
41
Polymorphisms in the TFAM and PGC1-I+ genes and their association with polycystic ovary syndrome among South Indian women. ( 29030253 )
2018
42
Abnormal irisin level in serum and endometrium is associated with metabolic dysfunction in polycystic ovary syndrome patients. ( 29972694 )
2018
43
Association between depression, symptom experience and quality of life in polycystic ovary syndrome. ( 29969586 )
2018
44
The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study. ( 29416587 )
2018
45
The preliminary association study of ADIPOQ, RBP4, and BCMO1 variants with polycystic ovary syndrome and with biochemical characteristics in a cohort of Polish women. ( 29428584 )
2018
46
Thymoquinone ameliorates some endocrine parameters and histological alteration in a rat model of polycystic ovary syndrome. ( 29942936 )
2018
47
A Retrospective Study of Letrozole Treatment Prior to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome Undergoing In Vitro Fertilization at Risk of Ovarian Hyperstimulation Syndrome. ( 29925074 )
2018
48
Circulating insulin-like peptide 5 levels and its association with metabolic and hormonal parameters in women with polycystic ovary syndrome. ( 29956214 )
2018
49
Improving care for women with polycystic ovary syndrome. ( 29933923 )
2018
50
Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome. ( 29428311 )
2018

Variations for Polycystic Ovary Syndrome

ClinVar genetic disease variations for Polycystic Ovary Syndrome:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CAPN10 NM_023083.3(CAPN10): c.471-187T> C single nucleotide variant risk factor rs2975760 GRCh37 Chromosome 2, 241531163: 241531163
2 CAPN10 NM_023083.3(CAPN10): c.471-187T> C single nucleotide variant risk factor rs2975760 GRCh38 Chromosome 2, 240591746: 240591746

Expression for Polycystic Ovary Syndrome

Search GEO for disease gene expression data for Polycystic Ovary Syndrome.

Pathways for Polycystic Ovary Syndrome

GO Terms for Polycystic Ovary Syndrome

Cellular components related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 8.62 INS PRL

Biological processes related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.95 GDF9 IGF1 INS INSR PRL
2 regulation of signaling receptor activity GO:0010469 9.88 GDF9 GNRH1 IGF1 INS PRL
3 steroid metabolic process GO:0008202 9.73 CYP11A1 CYP17A1 CYP21A2
4 activation of protein kinase B activity GO:0032148 9.61 IGF1 INS INSR
5 positive regulation of mitotic nuclear division GO:0045840 9.58 IGF1 INS INSR
6 steroid biosynthetic process GO:0006694 9.56 CYP11A1 CYP17A1 CYP19A1 CYP21A2
7 male sex determination GO:0030238 9.54 GNRH1 INSR
8 positive regulation of glycolytic process GO:0045821 9.54 IGF1 INS INSR
9 amyloid-beta clearance GO:0097242 9.52 INSR MSR1
10 neuron projection maintenance GO:1990535 9.51 INS INSR
11 positive regulation of glycogen biosynthetic process GO:0045725 9.5 IGF1 INS INSR
12 ovulation cycle GO:0042698 9.49 GNRH1 PRL
13 positive regulation of respiratory burst GO:0060267 9.46 INS INSR
14 glucocorticoid biosynthetic process GO:0006704 9.33 CYP11A1 CYP17A1 CYP21A2
15 positive regulation of glucose import GO:0046326 9.26 CAPN10 IGF1 INS INSR
16 sterol metabolic process GO:0016125 8.92 CYP11A1 CYP17A1 CYP19A1 CYP21A2

Molecular functions related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.62 CYP11A1 CYP17A1 CYP19A1 CYP21A2
2 iron ion binding GO:0005506 9.56 CYP11A1 CYP17A1 CYP19A1 CYP21A2
3 hormone activity GO:0005179 9.46 GNRH1 IGF1 INS PRL
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.26 CYP11A1 CYP17A1 CYP19A1 CYP21A2
5 insulin-like growth factor receptor binding GO:0005159 8.8 IGF1 INS INSR

Sources for Polycystic Ovary Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....